Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664943 | 0.90 | GPR119 (0.42) | GPR119TBK1IKBKEESR2NR1H2 | |
| SCHEMBL5661929 | 0.87 | GPR119 (0.54) | GPR119TBK1IKBKEESR2NR1H2 | |
| SCHEMBL5662475 | 0.84 | GPR119 (0.48) | GPR119TBK1IKBKEESR2NR1H2 | |
| SCHEMBL5427401 | 0.80 | GPR119 (0.43) | GPR119TBK1IKBKEESR2NR1H2 | |
| SCHEMBL5660144 | 0.79 | ESR2 (0.48) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5171654 | 0.78 | ESR2 (0.47) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5665173 | 0.77 | HRH3 (0.42) | — | |
| SCHEMBL5663741 | 0.77 | GPR119 (0.47) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5181709 | 0.76 | NR1H2 (0.45) | GPR119ESR2NR1H2WNT3ANPC1 | |
| SCHEMBL4924504 | 0.75 | GPR119 (0.49) | GPR119TBK1IKBKEESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | GPR119 130/4885TBK1 2326/4885IKBKE 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.